The Latino Coalition Against COVID-19

The Latino Coalition Against COVID-19 (LCAC19) is a national community-led, non-partisan, collaborative movement to build health equity in Latinx communities.

We join together with other organizations, task forces, coalitions, and alliances to build community capacity, combat misinformation, and amplify local voices to a national level.


Active Projects


SaludConTech is a community that empowers its members to build technology-assisted community-based solutions that promote wellness and eliminate health inequities in the Latinx community. Its annual symposium highlights population health-based approaches that utilize technology to promote wellness and eliminate health inequities in the Latinx community.

The COVID-19 Digital Compañero Program

For those without internet access, the COVID-19 isolation is not merely an inconvenience but a potentially life-threatening situation. While many have the privilege to work and learn from home, countless others are without any means of accessing vital information or resources required for families to thrive.

The COVID-19 Digital Compañero Program is an innovative approach to meet the needs of community members that continue to be digitally excluded.

person getting vaccinated

#Vacunateya: Latinx Physicians Proud To Be Vaccinated

Work With Us

You change the world. We do the rest. Explore fiscal sponsorship at PHI.

Bring Your Work to PHI

Support Us

Together, we can accelerate our response to public health’s most critical issues.


Find Employment

Begin your career at the Public Health Institute.

See Jobs


Breakthrough Infection Study of Over 600,000 Veterans Shows Declining COVID-19 Vaccine Protection

A new pre-print study of over 600,000 veterans by researchers from PHI and the Veterans Affairs Medical Center finds that overall COVID-19 vaccine protection declined significantly between February and August 2021. Declines were greatest for the Johnson & Johnson vaccine (from 88% in March to 3% in August), followed by PfizerBioNTech (91% to 50%) and Moderna (92% to 64%).


Continue to